This company has been marked as potentially delisted and may not be actively trading. Lionheart Acquisition Co. II (LCAP) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrendsBuy This Stock LCAP vs. FOLD, KNSA, TVTX, PGNY, CNMD, ATEC, RXRX, BEAM, SUPN, and CLOVShould you be buying Lionheart Acquisition Co. II stock or one of its competitors? The main competitors of Lionheart Acquisition Co. II include Amicus Therapeutics (FOLD), Kiniksa Pharmaceuticals (KNSA), Travere Therapeutics (TVTX), Progyny (PGNY), CONMED (CNMD), Alphatec (ATEC), Recursion Pharmaceuticals (RXRX), Beam Therapeutics (BEAM), Supernus Pharmaceuticals (SUPN), and Clover Health Investments (CLOV). These companies are all part of the "medical" sector. Lionheart Acquisition Co. II vs. Amicus Therapeutics Kiniksa Pharmaceuticals Travere Therapeutics Progyny CONMED Alphatec Recursion Pharmaceuticals Beam Therapeutics Supernus Pharmaceuticals Clover Health Investments Lionheart Acquisition Co. II (NASDAQ:LCAP) and Amicus Therapeutics (NASDAQ:FOLD) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, valuation, earnings, profitability, media sentiment, institutional ownership, risk, community ranking and dividends. Which has better earnings and valuation, LCAP or FOLD? Lionheart Acquisition Co. II has higher earnings, but lower revenue than Amicus Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioLionheart Acquisition Co. IIN/AN/A$3.21MN/AN/AAmicus Therapeutics$543.14M3.59-$151.58M-$0.09-70.44 Which has more risk & volatility, LCAP or FOLD? Lionheart Acquisition Co. II has a beta of 0.08, indicating that its stock price is 92% less volatile than the S&P 500. Comparatively, Amicus Therapeutics has a beta of 0.64, indicating that its stock price is 36% less volatile than the S&P 500. Does the media favor LCAP or FOLD? In the previous week, Amicus Therapeutics had 10 more articles in the media than Lionheart Acquisition Co. II. MarketBeat recorded 10 mentions for Amicus Therapeutics and 0 mentions for Lionheart Acquisition Co. II. Amicus Therapeutics' average media sentiment score of 1.57 beat Lionheart Acquisition Co. II's score of 0.00 indicating that Amicus Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Lionheart Acquisition Co. II Neutral Amicus Therapeutics Very Positive Do analysts rate LCAP or FOLD? Amicus Therapeutics has a consensus price target of $16.22, suggesting a potential upside of 155.87%. Given Amicus Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Amicus Therapeutics is more favorable than Lionheart Acquisition Co. II.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Lionheart Acquisition Co. II 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Amicus Therapeutics 0 Sell rating(s) 3 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.70 Is LCAP or FOLD more profitable? Lionheart Acquisition Co. II has a net margin of 0.00% compared to Amicus Therapeutics' net margin of -10.62%. Amicus Therapeutics' return on equity of 12.44% beat Lionheart Acquisition Co. II's return on equity.Company Net Margins Return on Equity Return on Assets Lionheart Acquisition Co. IIN/A -44.30% 1.39% Amicus Therapeutics -10.62%12.44%2.60% Does the MarketBeat Community favor LCAP or FOLD? Amicus Therapeutics received 533 more outperform votes than Lionheart Acquisition Co. II when rated by MarketBeat users. CompanyUnderperformOutperformLionheart Acquisition Co. IIN/AN/AAmicus TherapeuticsOutperform Votes53372.81% Underperform Votes19927.19% SummaryAmicus Therapeutics beats Lionheart Acquisition Co. II on 10 of the 12 factors compared between the two stocks. Get Lionheart Acquisition Co. II News Delivered to You Automatically Sign up to receive the latest news and ratings for LCAP and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart LCAP vs. The Competition Export to ExcelMetricLionheart Acquisition Co. IIBusiness Services IndustryMedical SectorNASDAQ ExchangeMarket Cap$472.59M$152.71M$5.38B$8.39BDividend YieldN/AN/A5.21%4.10%P/E RatioN/A1.0026.7619.71Price / SalesN/A33.42389.94117.54Price / Cash20.6411.7038.2534.62Price / Book-8.994.186.804.50Net Income$3.21M$1.30M$3.23B$248.18M Lionheart Acquisition Co. II Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)LCAPLionheart Acquisition Co. IIN/A$25.61-1.5%N/A+3,586.7%$472.59MN/A0.003FOLDAmicus Therapeutics4.0062 of 5 stars$6.10-1.8%$16.22+165.9%-36.0%$1.88B$543.14M-33.89480News CoveragePositive NewsKNSAKiniksa Pharmaceuticals2.9518 of 5 stars$25.85-3.7%$38.80+50.1%+34.8%$1.88B$481.17M-184.63220Positive NewsInsider TradeTVTXTravere Therapeutics2.9838 of 5 stars$21.14-1.9%$31.79+50.4%+151.1%$1.88B$273.53M-5.16460Positive NewsPGNYProgyny1.5002 of 5 stars$21.83-0.8%$23.45+7.4%-22.8%$1.87B$1.21B37.64310Positive NewsCNMDCONMED4.1173 of 5 stars$60.00-1.2%$62.20+3.7%-23.3%$1.86B$1.32B14.154,100Positive NewsDividend AnnouncementATECAlphatec4.0655 of 5 stars$12.65-0.2%$17.89+41.4%+18.5%$1.85B$642.27M-9.88700Positive NewsInsider TradeRXRXRecursion Pharmaceuticals2.4162 of 5 stars$4.53-2.4%$7.60+67.8%-57.0%$1.82B$59.82M-2.96400Positive NewsGap DownBEAMBeam Therapeutics3.1284 of 5 stars$18.06-1.0%$48.75+169.9%-30.6%$1.82B$63.58M-10.26510Positive NewsSUPNSupernus Pharmaceuticals2.6137 of 5 stars$31.67-1.5%$36.00+13.7%+16.3%$1.77B$668.00M29.60580Positive NewsCLOVClover Health Investments2.6899 of 5 stars$3.43-1.2%$4.83+40.9%+279.6%$1.75B$1.37B-17.15680Positive News Related Companies and Tools Related Companies FOLD Alternatives KNSA Alternatives TVTX Alternatives PGNY Alternatives CNMD Alternatives ATEC Alternatives RXRX Alternatives BEAM Alternatives SUPN Alternatives CLOV Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:LCAP) was last updated on 5/22/2025 by MarketBeat.com Staff From Our PartnersJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredThe Prophet's Newest PredictionA storm is brewing in the markets: new tariffs, recession warnings, and panic in the headlines. That’s when pu...Stansberry Research | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredFeds Just Admitted It—They Can Take Your CashThe Government Just Said Your Money Isn't Yours That's right—According to the DOJ, YOUR hard-earned money i...Priority Gold | SponsoredThis Is The Moment You Betray Trump (Or Prove Them Wrong)They said you wouldn’t last—that Bidenflation, Wall Street selloffs, and DEI funds would break your loyalty to...Colonial Metals | SponsoredTrump + Musk = AI’s turning pointTrump may not code… but he knows how to pick winners. And according to insiders, his administration is prep...True Market Insiders | SponsoredThe Collapse Has Already Started — Your 401(k) Is NextThere's a major heist happening on American wealth in real time. Except this one doesn't involve masks or v...American Hartford Gold | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lionheart Acquisition Co. II Please log in to your account or sign up in order to add this asset to your watchlist. Share Lionheart Acquisition Co. II With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
